ALK-Abelló A/S Asset Resilience Ratio

Latest as of September 2019: 0.98%

ALK-Abelló A/S asset resilience ratio. ALK-Abelló A/S (ALK-B) has an Asset Resilience Ratio of 0.98% as of September 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of ALK-Abelló A/S for a breakdown of total debt and financial obligations.

Liquid Assets

Dkr50.00 Million
≈ $7.82 Million USD Cash + Short-term Investments

Total Assets

Dkr5.09 Billion
≈ $796.52 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of ALK-Abelló A/S (2007–2019)

Asset resilience ratio of ALK-Abelló A/S from 2007 to 2019. This chart shows how ALK-Abelló A/S's Asset Resilience Ratio has changed over time. See ALK-B free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down ALK-Abelló A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALK-Abelló A/S assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Dkr0.00 0%
Short-term Investments Dkr50.00 Million 0.98%
Total Liquid Assets Dkr50.00 Million 0.98%

Asset Resilience Insights

  • Limited Liquidity: ALK-Abelló A/S maintains only 0.98% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

ALK-Abelló A/S Industry Peers by Asset Resilience Ratio

Compare ALK-Abelló A/S's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 6.69%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.76%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

ALK-Abelló A/S Asset Resilience Ratio by Year (2007–2019)

ALK-Abelló A/S asset resilience ratio by year from 2007 to 2019. The table below shows the annual Asset Resilience Ratio data for ALK-Abelló A/S.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2019-12-31 -2.91% Dkr-160.00 Million
≈ $-25.03 Million
Dkr5.50 Billion
≈ $859.73 Million
-4.97pp
2018-12-31 2.06% Dkr100.00 Million
≈ $15.65 Million
Dkr4.87 Billion
≈ $761.16 Million
-9.02pp
2017-12-31 11.07% Dkr549.00 Million
≈ $85.90 Million
Dkr4.96 Billion
≈ $775.72 Million
-0.35pp
2016-12-31 11.42% Dkr548.00 Million
≈ $85.74 Million
Dkr4.80 Billion
≈ $750.84 Million
+1.26pp
2015-12-31 10.16% Dkr432.00 Million
≈ $67.59 Million
Dkr4.25 Billion
≈ $665.26 Million
+4.08pp
2014-12-31 6.08% Dkr208.00 Million
≈ $32.54 Million
Dkr3.42 Billion
≈ $534.93 Million
-9.09pp
2007-12-31 15.17% Dkr428.00 Million
≈ $66.96 Million
Dkr2.82 Billion
≈ $441.37 Million
--
pp = percentage points

About ALK-Abelló A/S

CO:ALK-B Denmark Biotechnology
Market Cap
$7.81 Billion
Dkr49.92 Billion DKK
Market Cap Rank
#2562 Global
#16 in Denmark
Share Price
Dkr248.00
Change (1 day)
+0.57%
52-Week Range
Dkr192.30 - Dkr270.40
All Time High
Dkr270.40
About

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more